Chronic Hyperglycemia and Glucose Toxicity: Pathology and Clinical Sequelae

References

• . American Diabetes Association. Data from the 2011 National Diabetes Fact Sheet 2011. http://www.diabetes.org/diabetes-basics/diabetes-statistics/?utm_source=WWW&utm_medium=DropDownDB&utm_content=Statistics&utm_campaign=CON. Accessed June 29, 2012
   Google Scholar
• . World Health Organization. WHO Diabetes Fact Sheet 2011. http://www.who.int/mediacentre/factsheets/fs312/en/index.html. Accessed June 29, 2012
   Google Scholar
• . Brownlee M. A radical explanation for glucose-induced beta cell dysfunction. J Clin Invest. 2003;112(12):1788–1790
   Google Scholar
• . Guillausseau PJ, Meas T, Virally M, Laloi—Michelin M, Médeau V Kevorkian JP. Abnormalities in insulin secretion in type 2 diabetes mellitus. Diabetes Metab. 2008;34( suppl 2): S43–S48
   PubMed Web of Science ®Google Scholar
• . Weir GC, Bonner—Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes. 2004;53( suppl 3): S16–S21
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773–795
   PubMed Web of Science ®Google Scholar
• . Poitout V, Hagman D, Stein R, Artner I, Robertson RP, Harmon JS. Regulation of the insulin gene by glucose and fatty acids. J Nutr. 2006;136(4):873–876
   PubMed Web of Science ®Google Scholar
• . Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond). 2005;109(2):143–159
   PubMed Web of Science ®Google Scholar
• . Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–1625
   PubMed Web of Science ®Google Scholar
• . Brown A, Reynolds LR, Bruemmer D. Intensive glycemic control and cardiovascular disease: an update. Nat Rev Cardiol. 2010;7(7):369–375
   Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2011;34( suppl 1):S11–S61
   PubMed Web of Science ®Google Scholar
• . Kawahito S, Kitahata H, Oshita S. Problems associated with glucose toxicity: role of hyperglycemia-induced oxidative stress. World J Gastroenterol. 2009;15(33):4137–4142
   Google Scholar
• . Verkhratsky A, Fernyhough P. Mitochondrial malfunction and Ca2+ dyshomeostasis drive neuronal pathology in diabetes. Cell Calcium. 2008;44(1):112–122
   PubMed Web of Science ®Google Scholar
• . Di Mario U, Pugliese G. 15th Golgi lecture: from hyperglycaemia to the dysregulation of vascular remodelling in diabetes. Diabetologia. 2001;44(6):674–692
   Google Scholar
• . Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 2003;108(12):1527–1532
   PubMed Web of Science ®Google Scholar
• . van den Oever IA, Raterman HG, Nurmohamed MT, Simsek S. Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus. Mediators Inflamm. 2010;2010:792393
   PubMed Web of Science ®Google Scholar
• . Beisswenger PJ, Howell SK, Nelson RG, Mauer M, Szwergold BS. Alpha-oxoaldehyde metabolism and diabetic complications. Biochem Soc Trans. 2003;31(pt 6):1358–1363
   PubMed Web of Science ®Google Scholar
• . Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: the “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications? J Clin Endocrinol Metab. 2009;94(2):410–415
   PubMed Web of Science ®Google Scholar
• . Rossetti L, Shulman GI, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest. 1987;80(4):1037–1044
   PubMed Web of Science ®Google Scholar
• . Marchetti P, Dotta F, Lauro D, Purrello F. An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment. Regul Pept. 2008;146(1–3):4–11
   Google Scholar
• . Cabrera O, Berman DM, Kenyon NS, Ricordi C, Berggren PO, Caicedo A. The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci USA. 2006; 103(7):2334–2339
   PubMed Web of Science ®Google Scholar
• . Robertson RP, Harmon J, Tran PO, Poitout V. Beta-cell glucose toxicity lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes. 2004;53( suppl 1):S119–S124
   PubMed Web of Science ®Google Scholar
• . Del Guerra S, Lupi R, Marselli L, . Functional and molecular defects of pancreatic islets in human type 2 diabetes. Diabetes. 2005;54(3):727–735
   Google Scholar
• . Marchetti P, Del Guerra S, Marselli L, . Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab. 2004;89(11):5535–5541
   Google Scholar
• . Butler AE, Janson J, Bonner—Weir S, Ritzel RRizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52(1):102–110
   PubMed Web of Science ®Google Scholar
• . Biarnes M, Montolio M, Nacher y Raurell M, Soler J, Montanya E. Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Diabetes. 2002;51(1):66–72
   PubMed Web of Science ®Google Scholar
• . Bagust A, Beale S. Deteriorating beta-cell function in type 2 diabetes: a long-term model. QJM. 2003;96(4):281–288
   PubMed Web of Science ®Google Scholar
• . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329(14):977–986
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Cleary PA, Backlund JY, ; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–2653
   PubMed Web of Science ®Google Scholar
• . Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med. 2000;342(6):381–389
   Google Scholar
• . Writing Team for the Diabetes Control Complications Trial/Epidemiology of Diabetes Interventions Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290(16):2159–2167
   PubMedGoogle Scholar
• . The Diabetes Control Complications Trial/Epidemiology of Diabetes Interventions Complications (DCCT/EDIC) Research Group; Nathan DM, Zinman B, Cleary PA, et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications experience (1983–2005). Arch Intern Med. 2009;169(14):1307–1316
   Google Scholar
• . Holman RR, Paul SK, Bethel MA, Matthews DRNeil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–1589
   PubMed Web of Science ®Google Scholar
• . Duckworth W, Abraira C, Moritz T, ; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–139
   PubMed Web of Science ®Google Scholar
• . ; ADVANCE Collaborative GroupPatel A, MacMahon S, Chalmers J. . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–2572
   PubMed Web of Science ®Google Scholar
• . Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24): 2545–2559
   PubMed Web of Science ®Google Scholar
• . Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009;94(9):3171–3182
   PubMed Web of Science ®Google Scholar